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Hematopoietic stem cell transplantation (HSCT) is a treatment paradigm that has long been utilized for cancers of
the blood and bone marrow but has gained some traction as a treatment paradigm for multiple sclerosis (MS).
Success in the treatment of patients with this approach has been reported primarily when strict inclusion criteria
are imposed that have eventuated a more precise understanding of MS pathophysiology, thereby governing trial
design. Moreover, enhancing the yield and purity of hematopoietic stem cells during isolation along with the utility
of appropriate conditioning agents has provided a clearer foundation for clinical translation studies. To support this
approach, preclinical data derived from animal models of MS, experimental autoimmune encephalomyelitis, have
provided clear identification of multipotent stem cells that can reconstitute the immune system to override the
autoimmune attack of the central nervous system. In this review, we will discuss the rationale of HSCT to treat MS
by providing the benefits and complications of the clinically relevant protocols, the varying graft types, and
conditioning regimens. However, we emphasize that future trials based on HSCT should be focused on specific
therapeutic strategies to target and limit ongoing neurodegeneration and demyelination in progressive MS, in the
hope that such treatment may serve a greater catchment of patient cohorts with potentially enhanced efficiency
and lower toxicity. Despite these future ambitions, a proposed international multicenter, randomized clinical trial of
HSCT should be governed by the best standard care of treatment, whereby MS patients are selected upon strict
clinical course criteria and long-term follow-up studies of patients from international registries are imposed to
advocate HSCT as a therapeutic option in the management of MS.Background
Multiple sclerosis (MS) has been defined as an auto-
immune disease of the central nervous system (CNS).
Although the etiology of MS has not been clearly eluci-
dated, it is generally agreed that autoreactive T cells, ac-
tivated by either self-reactive or cross-reactive antigens,
migrate through the blood–brain barrier (BBB) and
trigger an inflammatory cascade that ultimately leads to
demyelination and progressive neurodegeneration of
the CNS [1]. Pathologically, the brain tissue of autopsy
patients exhibits inflammatory infiltrates with the de-
generation of myelin, reactive gliosis, and axonal degener-
ation [2, 3]. Neurological disability is manifest in a number
of symptoms, including blurred vision and diplopia, sensory
disturbances (e.g., paresthesia and dysesthesia), heat intoler-
ance, hemiparesis or paraparesis, vertigo and dizziness, lack* Correspondence: steven.petratos@monash.edu
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tinence, cognitive impairment, and memory loss.
As with most autoimmune disorders, MS predomin-
antly affects young females between 20 and 40 years of
age with the prevalence being 80–120/100,000 popula-
tion with a lifetime risk of 1 in 400 [4, 5]. MS is classi-
fied into four main subtypes: relapsing remitting (RR),
secondary progressive (SP), primary progressive (PP),
and progressive relapsing (PR) [2]. Over 80 % of patients
with MS begin with a RR course characterized by re-
lapses that result from inflammation, followed by incom-
plete or complete remission. After 5–15 years from its
onset, 50 % of patients enter SP-MS, where pre-existing
neurological deficits gradually worsen from the onset
with subsequent superimposed relapses. The latter is
characterized by axonal degeneration and loss, leading
to gliosis and brain atrophy. MS follows the PP phase in
15 % of individuals, in which disability accumulates fas-
ter than in the early RR course. PR-MS is the least fre-
quent form of MS and is characterized by a steadyarticle is distributed under the terms of the Creative Commons Attribution 4.0
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enced by the patient [3, 6].
Currently there is no cure for MS, but a number of
therapeutic agents are used to treat specific symptoms
and sequelae of the disease, with most designed to pre-
vent the progression of disability by targeting immune
activation and inflammation [3]. Conventionally, MS can
be treated by chemotherapeutic agents for chronic im-
munosuppression, corticosteroids for the management
of acute inflammatory relapses, and immunotherapeutic
interventions for immunomodulation, using drugs such
as natalizumab, interferon beta, glatiramer acetate, di-
methyl fumarate, alemtuzumab, and fingolimod [3].
These treatments are used to diminish the patient’s re-
lapses both in frequency (e.g., glatiramer, interferon beta,
and more recent types of monoclonal antibodies given
regularly) and in severity (e.g., corticosteroids taken
acutely) [7]. Among the most promising strategies used in
regenerative medicine, hematopoietic stem cell transplant-
ation (HSCT) prevails as an excellent but controversial
therapeutic regime to limit the deleterious pathology fol-
lowing an autoimmune attack. It has been posited that
HSCT may in fact be useful for improving the neuro-
logical function of MS patients by the replacement of
autoreactive cells with healthy cells, potentially removing
the patient’s genetic susceptibility to develop MS [8].
Hematopoietic stem cell transplantation
HSCT has been harnessed for more than 40 years in the
clinic as an effective therapeutic approach. In 1995, the
first transplantation of hematopoietic stem cells (HSCs)
was suggested as a treatment for MS after hypothesizing
that an immune-mediated attack on myelin causes
pathologic events in MS [9]. Two years later in the
United States, HSCT was performed in 15 MS patients
with a progressive form [10]. HSCs capable of self-
renewal when effectively transplanted and engrafted in
the human can differentiate into all of the cells found in
the hematopoietic system. They are divided into two dif-
ferent types: long-term (LT) and short-term (ST) subtypes
(Fig. 1). LT-HSCs have the ability to self-renew and pro-
vide all hematopoietic lineages during the life of an indi-
vidual. ST-HSCs, as the name suggests, are incapable of
long-term self-renewal under normal conditions, but they
do provide the ability to reconstitute hematopoiesis of cer-
tain lineages over a finite period [11].
Isolation of HSCs
HSCs represent rare cell populations that exist in the bone
marrow (BM) and constitute approximately 0.01 % of total
nucleated cells [12]. They can afford the complete restor-
ation of all blood-cell lineages after BM ablation in vivo
and the improvement of the MS patients’ immunity. Based
on this definition, several xenogenic and congenic assayshave been established to quantitate and detect human and
mouse HSCs [13].
HSC populations isolated from their stem cell niche
differ morphologically. They can therefore be separated
using several methods based on their physical properties,
on their physiological properties, or using specific cell
surface markers [12]. The study of HSCs has been ex-
pedited in the last 20 years by the development of vari-
ous isolation techniques such as flow cytometry and
the availability of newly developed monoclonal anti-
bodies more specific to HSCs, with the most successful
approaches varying in selectivity, choice of separation
parameters, and capacity [13]. These methods are clas-
sified into nonantibody-based and antibody-based HSC
selection methods.
HSC selection methods without the need of antibodies
The most common technique for separating HSCs,
based on differences in their cell size and density, is
density gradient centrifugation [13, 14]. HSC suspen-
sions are centrifuged through a density medium such as
Percell (GE Healthcare life Sciences, Uppsala, Sweden)
or a mixture of Ficoll (GE Healthcare life Sciences) and
Hypaque (GE Healthcare life Sciences), resulting in the
separation of denser mature cells such as granulocytes
and erythrocytes. However, this method results in loss of
HSCs due to overlapping densities of lymphocytes and
stem cells. Cytotoxic drugs, such as hydroxyurea and 5-
fluorouracil (5-FU), can be used to selectively kill mature
cells which are undergoing cell division and this ap-
proach has been used to enrich mouse HSCs before
other selection techniques. Hydroxyurea inhibits the ac-
tivity of ribonucleotide reductase, whereas 5-FU inhibits
thymidylate synthase, the end result being decreased
production of deoxyribonucleotides, which are used in
replication. Since most HSCs are quiescent under
steady-state conditions, they are resistant to cytotoxic
drugs. Alkylating agents such as phosphamide can inter-
fere with DNA replication and can also be used to elim-
inate dividing cells. In addition, HSCs express aldehyde
dehydrogenase (ALDH), which is an intracellular en-
zyme that confers resistance against phosphamides [13].
It has been demonstrated that fraction 25, lineage-
depleted, ALDH bright cells are stable for long-term re-
constitution of lymphohematopoietic cells at 10 cells per
animal. These techniques can be utilized to distinguish
primitive HSCs from multiprogenitors demonstrated
through colony-forming spleen assays (CFU-S) [14]. Fur-
thermore, HSCs are enriched by the activity of ALDH;
the expression of this enzyme overlaps with the expres-
sion of CD34 in the BM cells of adult humans, demon-
strating that the activity of this enzyme is a marker for
primitive HSCs as well as lineage-committed progenitor
cells [13].
Fig. 1 Hematopoietic hierarchy model. Hematopoietic stem cells (HSCs) are divided into long-term (LT)-HSC and short-term (ST)-HSC types. A LT-HSC
with long-term self-renewal activity is converted into a ST-HSC and then HSCs give rise to a multipotent progenitor (MPP). A MPP commits in bone
marrow to become either common myeloid progenitor (CMP) or common lymphoid progenitor (CLP). The CMP and CLP give rise to mature blood
cells in peripheral blood, such as granulocytes, red blood cells (RBC), platelets, monocytes, T cells, B cells, and natural killer (NK) cells [7]
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The antibody-dependent methods for the isolation of
HSCs rely on the availability of monoclonal antibodies di-
rected against specific cell surface markers followed by
isolation using either fluorescence-activated cell sorting
(FACS) or magnetic-activated separation (MACS) [13].
Utilizing flow cytometry, fluorescently tagged antibodies
are used to identify surface proteins, which are expressed
at specific stages of development, permitting distinctions
among phenotypically homogeneous cell populations.
Using MACS, antibodies directed against a surface antigen
of interest are coated with magnetic nanoparticles. The
cells are separated by placing the cell suspension into a
magnetic field following antibody incubation. Both FACS
and MACS use positive and negative selection. These
techniques are typically applied to provide a sufficient
yield and purity of HSCs for clinical transplantation pur-
poses by eliminating the vast majority of mature cells. Fur-
thermore, these techniques can be adapted for either
positive or negative selection of HSCs [13].Cell surface markers of human and mice HSCs
Although there are several shared biological similar-
ities between human and mouse HSCs, there are
differences in the purification strategies implemented
for human HSCs as opposed to the experimental iso-
lation of mouse HSCs when utilized for therapeutic
applications. Although the human cord blood or adult
BM side population showed very low HSC activity
in vitro, the mouse BM side population represents
significant enrichment for hematopoietic activity. An-
other disparity is that positive selection through the
enrichment of human CD34+CD38– cells has been
readily utilized for clinical purposes enriching the
populations of progenitors and HSCs [13]. However,
it has been shown that only low levels of CD34 are
expressed on mouse LT-HSCs [12]. An outline of
readily utilized markers for both human and mouse
HSCs is presented in Table 1. The main HSC markers
that distinguish mouse and human cells are presented
in Table 2.
Table 1 Surface profile of HSCs in mouse and human [7]
CD marker Synonym Main expression Function
CD3 T3, leu4 T cell Mediated T-cell signal transduction and used in Lin
cocktail
CD4 T4, leu3 MHC-II, T cell, macrophage/monocytes, dendritic
cells
Initiate early phase of T-cell activation and used in Lin
cocktail
CD8 T8 MHC-I, T-cell subsets T-cell-mediated killing, and used in Lin cocktail
CD11b CR3, MAC 1 Macrophage/monocytes, dendritic cells,
granulocytes, NK cells
Phagocytosis, adhesion interaction of macrophage/
monocytes, granulocytes, and used in Lin cocktail
CD11c CR4 Macrophage/monocytes, granulocytes, NK cells Similar to CD11b, cell–cell interaction during
inflammatory response, and used in Lin cocktail
CD34 Gp105/120, Mucosialin Precursor of hematopoietic cells, endothelial cells Cell adhesion
CD38 T10 Lymphoid cells, macrophage/monocytes Cell adhesion and transduction
CD45R B220, Ly-5 T cells and mostly B cells T-cell and B-cell antigen receptor-mediated signaling,
and used in Lin cocktail
CD59 MIRL T cells, NK cells, granulocytes, erythroid,
macrophage/monocytes
Complement cascade regulation
CD117 c-Kit HSCs/progenitor cells and mast cells Survival of mast cells, activation, proliferation, and
chemotaxis
CD161 NK1.1 NK cells NK cell-mediated cytotoxicity, proliferation, and used
in Lin cocktail
SCA-1 Ly6A/E HSCs, HPCs, some lymphoid and myeloid cells Mice HSCs are positive
Gr1 Ly-6G Monocytes and granulocytes Used in Lin cocktail
Ter119 Ly76 Erythroid cells Used in Lin cocktail
CD cluster of differentiation, c-Kit tyrosine-protein kinase receptor, CR complement receptor, HPC hematopoietic progenitor cell, HSC hematopoietic stem cell, leu
leucine, Lin lineage markers, Ly lymphocyte activation protein, MAC1 macrophage 1 antigen, MHC major histocompatibility complex, MIRL membrane inhibitor of
reactive lysis, NK natural killer, SCA-1 stem cell antigen-1
Bakhuraysah et al. Stem Cell Research & Therapy  (2016) 7:12 Page 4 of 12In mouse HSCs, most of the purification approaches
revolve around the positive selection markers, such as
stem cell antigen-1 (SCA-1) or the transmembrane
tyrosine-protein kinase receptor (c-Kit or CD117) and
negative markers for mature HSC lineages (e.g., CD3e,
CD4, CD8a, CD45R/B220, CD11b, CD11c, NK1.1,
TER119, and Gr-1). Removal of mature cells that express
lineage (lin) markers using an antibody cocktail leads to
the enrichment of blast cells, HSCs, and progenitor cells
from BM and blood [13]. Therefore, about 10 % of Lin–,
Sca-1+, and c-Kit+ (LSK) cells are bonafide LT-HSCs,
which are self-renewing cells and can grow in culture,
along with being able to be transduced ex vivo using len-
tiviral vectors [15]. However, CD34+ cells from mouse
BM are expressed on ST-HSCs, which rapidly die
ex vivo and then cannot be cultured [16]. Hence LSKTable 2 Main markers used to discriminate mouse and human
HSCs [10]
Cell surface markers
Mouse lin–, CD34–/low, CD38+, Sca-1+, c-Kit+, Thy-1, FGFR, CD201, CD105
Human lin–, CD34+, CD38–/low, CD133, c-Kit–/low, Thy-1+, CDCPI, VEGFR1
CD cluster of differentiation, CDCPI cubdomain-containing protein, c-Kit
tyrosine-protein kinase receptor, FGFR fibroblast growth factor receptor, HSC
hematopoietic stem cell, lin lineage markers, Sca-1 stem cell antigen-1, Thy-1
thymocytes, VEGFR1; vascular endothelial growth factor receptor 1cells are those selected for sorting by FACS for long-
term culture experiments.
In addition to the identification of cell surface markers,
the side population has been used to further enrich BM
for mouse or human HSCs based on their capability to ef-
flux the Hoechst nuclear dye via a membrane transport
pump (ATP-binding cassette family). The dye is reserved
at low levels in these cells in a highly active form when
compared directly with other types of BM cells [12, 13].
Rhodamine-123 (Rho) and Hoechst 33342 (Ho) are exam-
ples of effluxing specific fluorescent dyes. Rho–/low pre-
sents the majority of HSCs from adult mouse and human,
while this phenotype of Rho–/low is regulated correspond-
ingly to CD34 in murine HSCs [13]. According to Pearce
and Bonnet [17], it may be that there is no long-term re-
constitution established by utilizing either human HSCs
or the cord blood side population, although there is a sig-
nificant HSC enrichment when using the mouse stem cell
side population, which are primarily CD34–, highlighting
differences in the transplantation of HSCs in experimental
models when compared with those performed in the clin-
ical setting.
HSCT in a mouse model of MS
HSCT was clinically pursued in MS based on strong
data obtained from mouse models of autoimmune
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therapy. A series of experiments conducted in the early
1990s used the classical experimental autoimmune en-
cephalomyelitis (EAE) model, which has been widely
used to understand the mechanism of MS disease. It is
induced by immunization with the myelin oligodendro-
cyte glycoprotein (MOG), proteolipid protein (PLP), or
myelin basic protein (MBP) [8, 18].
EAE can be induced in C57BL/6 mice by immunizing
with the MOG35–55 peptide emulsified in complete
Freund’s adjuvant (CFA), resulting in a progressive paraly-
sis ascending from the tail to the forelimbs. The disease
progression in this model can thus be scored accordingly
and the immune-mediated pathology within the CNS can
be measured accurately. Furthermore, myelin damage and
CNS inflammation in this mouse model can be quantified
and visualized using histological analysis, in addition to
immunological assays to measure autoantibody reactivity
and specific T cells which can be used to validate certain
immune responses to the different myelin components
[19]. Recent research in autoimmune conditions is now
also investigating gene therapy as a possible option toFig. 2 Experimental procedure of bone marrow transplantation in experim
donor mice (C57Bl/6) 6–10 weeks old are cultured and ex vivo transduced
glycoprotein (MOG) gene and green fluorescent protein (GFP) driven by an
of these cells. Transplanted GFP-expressing cells into irradiated mice follow
their development or protection of disease, as well as chimerism [20]. LTR lcorrect the defective HSCs present prior to transplantation
[20]. The experimental procedure includes the isolation of
BM stem cells from donor mice that are transduced with
retrovirus encoding a specific antigen after culturing these
cells ex vivo. Transduced stem cells are then transferred to
conditioned recipient mice, following total body irradi-
ation (TBI), leaving them to engraft and regenerate the
hematopoietic system, including dendritic cells, B cells,
and T cells, all lineages being identified by flow cytome-
try (Fig. 2). Using this model, mice were resistant to
EAE induction after transferring transduced BM cells
with retrovirus encoding MOG [20].
The rationale of autologous hematopoietic stem cell
transplantation (auto-HSCT) for MS is based on using
chemotherapy to induce immunoablation, with subse-
quent reconstitution of the impaired immune system
through renewed self-tolerant cells [21]. A report in 1996
by van Gelder and van Bekkum [22] explored the use of
auto-HSCT in EAE, demonstrating that lymphocytes,
which are present in the autologous cells, might lead to
the occurrence of relapse after transplantation. An add-
itional report by van Bekkum in 2004 [23] explored theental autoimmune encephalomyelitis (EAE) mice. Isolated BM cells from
with a retroviral vector, which encodes the myelin oligodendrocyte
internal ribosomal entry site (IRES) to assist enumeration and tracking
ing their immunization with MOG35–55 to induce EAE are assessed in
ong terminal repeat, WT wild type
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and absence of disease relapse was seen in 70 % of cases.
The treatment was found to be most effective at the early
stages of autoimmune disease, whereas no effect was seen
in the later stages. High-dose TBI led to a better response;
however, TBI can lead to severe carcinogenic events at a
later stage. The use of cyclophosphamide and busulfan
also proved less effective than TBI [23].
In addition, the animal model study was conducted
to supplement the conventional nonspecific-dose im-
munosuppression; it involved the administration of
high-dose immunosuppressant (myeloablative chemo-
therapy) followed by HSCT, which effectively reduced
morbidity and mortality in this model. The transplant
experiments showed that EAE remissions were attained
in animals after high-dose TBI. Therefore, the use of
high-dose immunosuppressive agents in EAE led to a
better response as compared with TBI [24].
HSCT as a therapeutic option for MS
Over the last 20 years, HSCT was anticipated as a treat-
ment for MS patients by ablating or suppressing the en-
dogenous immune system. It is likely to beneficially
affect the inflammatory stage of the disease [25]. In the
1990s, auto-HSCT was suggested for the management of
refractory and severe autoimmune disease, including
MS. Only a few HSCT trials have implemented the use
of donor-derived HSC grafts or HLA-matched allogeneic
cell transplants because of the higher rate of mortality
and morbidity with graft versus host disease (GVHD)
than auto-HSCT. The role of HLA proteins is to direct
the response of T cells and they are important in the se-
lection of donors for allo-HSCT [26, 27].
Recently, several MS patients were treated with auto-
HSCT after exposure to high doses of immunosuppressive
drugs by using different procedures of HSC harvesting
and conditioning regimens [26–28]. In a BM graft, around
3–5 % of the cells are HSCs and the graft of peripheral
blood HSCs are rich in lymphocytes, granulocytes, and
monocytes. The procedure of transplantation is initiated
after collecting HSCs from the patient’s BM through sev-
eral aspirations performed under general or regional
anesthesia [29]. Otherwise, peripheral blood stem cells
(PBCS) can be mobilized from the BM into blood circula-
tion in large amounts by using chemotherapy and/or a
specific cytokine, such as granulocyte colony-stimulating
factor (G-CSF), and FLT3 ligand thyroid peroxidase
(TPO). In HSCT, this cytokine is injected into the donor
prior to harvesting stem cells to maximize HSC collection.
During the apheresis process, the donor’s blood is passed
through a device whereby CD34+ (a cluster of differenti-
ation mixture of HSCs, progenitor cells, and white blood
cells) is expunged, and then red blood cells are returned
to the donor. By using this method, 5–20 % of theextracted HSCs are suitable for treating patients with MS
[29]. These purified HSCs can be cryopreserved until the
patients are ready to undergo transplantation, estimated
to be between 2 and 6 weeks. In this process, administra-
tion of chemotherapy with or without immune-depleting
biological agents is vital for destroying the patient’s mature
immune lineage cells before infusing the cryopreserved
HSCs. Hematopoietic engraftment and recovery from
chemotherapy may take between 3 and 6 months [29]
(Fig. 3).
Immune reconstitution occurs via two key mecha-
nisms: homeostatic expansion of mature T cells and B
cells comprised in the graft; and de novo lymphopoiesis
of new engrafted HSCs [30]. In theory, ongoing MS
activity after HSCT may be caused by the expansion of
autoreactive lymphocytes. Procedures to diminish the
immune cell load in the graft may improve the outcome.
Therefore, the effect of using immune ablative condi-
tioning regimens to deplete lymphocytes in the graft
may be apparent following HSCTs [29]. However, when
adopting or developing pre-existing HSCT regimens for
novel indications, such as MS, consideration needs to be
given to cytogenetic abnormalities, to the patient’s med-
ical condition (e.g., age, status of performance and status
of disease), to an existing graft source, and to disease-
specific prognostic factors [31].
Muraro et al. [32] showed that using the auto-HSCT
myeloablative regimen can reconfigure the immune sys-
tem in mature MS patients by reconstituting the CD4+
T-cell lineage population. In myeloablative conditioning
regimens, patients are given chemotherapy with or with-
out TBI before transplantation. The purpose of this
process is to eliminate disease in the patient before HSC
infusion and suppression of the immune system, and it
requires stem cell support to rescue marrow function
and avoid aplasia-related death. However, the process is
restricted to patients younger than 50 years old due to
its toxic effect on non-BM organs (e.g., liver, heart, and
lung) [29].
On the other hand, Burt et al. [25] confirmed in their
study that the purpose of conditioning regimens in MS
is lymphoablative because the rationale of auto-HSCT
is to revive an antigen-naive immune system from the
patient’s HSCs; thus, myeloablative regimens are lethal
to HSCs. In addition, the rationale of nonmyeloablative
HSCT in MS is to suppress relapses by intervening prior
to the onset of irreversible progressive axonal degener-
ation, to prevent inflammation, and to reduce toxicity in
the older patient population. Such a regimen, being im-
munosuppressive in nature but without the myeloablative
side effects, can be designed to dampen the activity of the
immune system by using cyclophosphamide, fludarabine,
rabbit anti-thymocyte globulin (ATG), or CAMPATH-1H
(anti-lymphocyte antibodies), and/or by using the graft
Fig. 3 Autologous hematopoietic stem cell (HSC) transplantation in multiple sclerosis (MS) patients. The technique is initiated after collecting HSCs
from the patient’s BM through BM aspiration or peripheral blood leukopheresis achieved under general or regional anesthesia [29]. The collected HSC
grafts are cryopreserved in liquid nitrogen until they are required for transplantation [29]. The patient’s immune cells will be destroyed after high-dose
chemotherapy along with immune ablative conditioning regimens. The cryopreserved HSCs will be infused into the patient intravenously, and then
the reconstitution of the hematopoietic system will occur following 10–14 days after transplantation, with full recovery from chemotherapy occurring
between 3 and 6 months [29]
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depletion technology can change the composition of graft
cells but may lead to an elevated risk of treatment-related
infection for an intense conditioning regime [25]. Further-
more, the intensity of conditioning regimes may exert a
toxic effect on the CNS and this neurotoxicity has been
associated with radiation and busulfan treatment. There-
fore, it may stand to reason that moderating conditioning
regimes may provide a less toxic outcome for MS patients
when treated through HSCT [25].
Recently, powerful conditioning regimens followed by
auto-HSCT have been applied to aggressive MS. An ex-
ample of these is alemtuzumab, which is a monoclonal
antibody that targets the B-cell and/or T-cell compart-
ment. Alemtuzumab contributed to the depletion of
circulating lymphocytes that lead to the control of the
autoimmune response in MS patients after transplant-
ation, as well as preventing the development of GVHD
by diminishing cytotoxic effector cells [21]. However, it
has been noted that using this drug may lead to theinduction of secondary autoimmune sequelae [34].
Around 10 % of patients undergoing HSCT for auto-
immune illness have been observed to develop a
secondary autoimmune disease unrelated to their in-
duction for auto-HSCT within the first 2 years after
HSCT, although the primary autoimmune illness may
have been suppressed following the HSC graft [35].
Secondary autoimmune disease was found to be less
common in patients who undertook HSCT for MS but
more frequent in patients who undertook HSCT for
systemic lupus erythematosus [34]. Furthermore, im-
mune thrombocytopenic purpura (immune cytopenia)
may occur many years after HSCT. This may occur as a
result of the lymphocyte-depleting antibodies adminis-
tered during the conditioning of the HSC graft [36].
Secondary autoimmune disease occurred in around 4 %
of patients without having a lymphocyte-depleting
agent during the HSCT conditioning regimen, although
9 % of patients suffered from secondary autoimmune
disease after using ATG [36].
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effects of HSCT in MS
A specific study identifying the toxicity and feasibility of
auto-HSCT in 15 patients with SP-MS and RR-MS with
a median Expanded Disability Status Scale (EDSS) of 6
(range 4.5–6.5) determined that in two patients neuro-
logical deterioration with high fever continued, one pa-
tient sustained a transient neural deterioration, three
patients exhibited transient engraftment syndrome, one
patient had unsuccessful mobilization, and reactivation
of cytomegalovirus occurred in one patient. The EDSS
improved in three patients assessed at 1-year follow-up
after transplantation but remained constant in nine pa-
tients and worsened in two patients. According to mag-
netic resonance imaging (MRI), enhanced T1 lesion
disappeared in patients. This study demonstrated the
feasibility and acceptable toxicity of using auto-HSCT to
reduce the progression of MS. Long-term follow-up after
transplantation is vital for the health management of MS
patients [37].
A more recent study conducted by Shevchenko et al.
[38] set out to determine the long-term effectiveness and
safety of auto-HSCT in conjunction with high-dose im-
munosuppressive therapy (HDIT), along with a decreased
intensity BEAM condition regimen, for different types of
MS patients. Fassas et al. [39] pioneered BEAM (BCNU
(carmustine), cytarabine, etoposide, melphalan) as a con-
ditioning regimen for auto-HSCT, which includes carmus-
tine (bis-chloroethyl nitrosourea), etoposide, cytosine
arabinoside, and melphalan. This study involved 99 MS
patients (39 male and 60 female, mean age 35 years); 43 of
the patients were RR-MS, 35 were SP-MS, 18 were PP-
MS, and three were PR-MS with EDSS prior to graft of
3.5. Ninety-eight patients had a neurological improvement
or stabilization after 6 months of transplantation [38].
There were no transplanted deaths observed and the cu-
mulative incidence of disease progression was 16.7 % at
8 years post-transplantation. These studies were very fa-
vorable because 47 % of the patients improved in their
EDSS score (at least 0.5), as compared with the baseline,
and 45 % of MS patients were stable at median long-term
follow-up for more than 5 years in both the RR-MS and
progressive MS groups. Besides, the patient’s quality of life
improved in MS by using auto-HSCT with this specific
regimen [38]. The consistency observed in these long-
term clinical results associated with the quality of life en-
hancement for these patients reported by Bowen et al.
[24] advocates for the safety and efficiency of this treat-
ment approach in MS patients. In addition, a clinical study
was conducted by Guimarães et al. [40] to determine the
impact of auto-HSCT on health-related quality of life
(HRQL) in patients with PP-MS and SP-MS in Brazil [40].
Approximately 79 % of patients enrolled in these trials (27
patients) revealed neurological improvement 1 year aftertransplantation with significant improvement in the
HRQL, indicating that although HSCT involves compli-
cated procedures it impacts positively in MS patients
by improving their HRQL. Progression-free survival
after treatment with HSCT has been reported in 81 %
of SP-MS patients after 3 years and in 67 % of PP-MS
patients [40].
On the other hand, researchers in Greece released
long-term results from a single-center phase I/II trial of
auto-HSCT [41]. According to clinical and MRI data
from 35 patients with progressive MS treated with auto-
HSCT, researchers demonstrated that HSCT is a therapy
for aggressive cases but is not recommended for the vast
majority of MS patients with more common RR presen-
tations. Moreover, HSCT has a sustained and impressive
effect in suppressing disease activity after a medium
follow-up period of 11 (range 2–15) years. At 15 years,
disease (progression-free) survival was 44 % for patients
with active CNS disease and 10 % for those without.
There was an improvement in EDSS scores in 16 pa-
tients by 0.5–5.5 for a median of 2 years. However, the
EDSS from nine patients did not progress above baseline
scores and two patients died from transplant-related
complications. MRI data identified a significant reduction
in gadolinium-enhancing (Gd+) lesions after mobilization,
becoming maximal post-transplantation [41]. This study is
consistent with Saccardi et al. [42] on 178 patients from
45 centers.
Several studies have shown the effectiveness of using
HSCT for young patients with highly aggressive, malig-
nant forms of MS. This type of MS is rare and character-
ized by abnormally localized autoimmune processes in
the brain stem or upper cervical cord and/or intense in-
flammation resulting in rapid development of significant
disability or death in the early stages of the disease
course. Marburg variant MS is another demyelinating
disease with an equally ominous prognosis with malig-
nant MS, although it may differ histologically [43, 44].
Since 2011, researchers in the United Kingdom have
evaluated the effect of using pulsed cyclophosphamide
and nonmyeloablative auto-HSCT in the case of a se-
verely disabled 21-year-old female patient presenting
with malignant MS. This treatment led to improvement
in the patient, who suffered from a disturbance of sen-
sorimotor function in all four limbs. The results of her
neuroimaging showed demyelination with enhancement,
cerebrospinal fluid (CSF) was positive to oligoclonal bands
and demonstrated 47 lymphocytes, and serum was nega-
tive for aquaporin4 (Aq4) antibodies. Although the patient
experienced several treatments, such as alemtuzumab
with pulsed intravenous methylprednisolone (IVMP) and
plasma exchange, she continued to deteriorate. The pa-
tient underwent auto-HSCT after 2 months of treatment
with cyclophosphamide. The patient’s EDSS score was 8.5
Bakhuraysah et al. Stem Cell Research & Therapy  (2016) 7:12 Page 9 of 12at the time of transplantation but 1 year after treatment
the score decreased to 6.5, and she was able to walk.
According to this case report, using cyclophosphamide
prior to auto-HSCT is crucial for clinical improvement,
suppression of relapses, and stabilization of the lesion
burden, especially in highly active RR-MS patients [45].
This study is consistent with the study of Faguis et al.
[46] on nine patients with malignant RR-MS who
underwent auto-HSCT with BEAM condition followed
by cyclophosphamide, resulting in one relapse in 280
patient-months following HSCT. All patients had their
disability improve or stabilize, and most of the patients
showed no enhanced lesions during follow-up. Further-
more, Kimiskidis et al. [44] reported an improvement
and long-lasting clinical and radiological response in a
case with malignant MS who was treated with high-
dose chemotherapy plus ATG followed by auto-HSCT.
Results from several studies recommend nonmyeloabla-
tive HSCT to treat SP-MS and RR-MS mainly due to the
fact that HSCT has immunosuppressive and immuno-
modulatory effects, evident from a more diverse T-cell
clonal population in post-HSCT patients [47]. This occurs
due to the ability of HSCT to modulate autoimmunity
without the requirement to eradicate the full patient’s
hematopoietic cells (myeloablation regimen). In 2015, a
study by Burt et al. [48] focused on improving neuro-
logical disabilities and other clinical results of RR-MS pa-
tients using nonmyeloablative HSCT. This study included
191 MS patients; 123 patients had a RR course of the dis-
ease and 28 had SP-MS, with mean age of 36 years. Pa-
tients were treated at a single US institution between 2003
and 2014, and the researchers followed-up with patients
for 5 years. At year 4 post-transplantation, 64 % of patients
demonstrated improvement in the EDSS score from a pre-
transplant median of 4.0 to 2.5, neurological rating scale
scores increased from a pretransplant median of 74 to
87.5 in 34 patients, and the MS functional composite
scores were 0.45 (0.04–0.60) (p = 0.02). The brain T2 le-
sion volume reduced significantly from a pretransplant
median of 8.57 cm3 to 5.74 cm3 (p < 0.001) at the last
post-transplant assessment of MRI scans in 128 patients
with a mean follow-up of 27 months. In this study, the
quality-of-life short form based upon the 36 questionnaire
score was improved significantly in 132 patients from a
pretransplant median of 46 to 64 at year 2 post-transplant
as compared with the previous results of the AFFIRM
(The Natalizumab Safety and Efficacy in Relapsing Remit-
ting Multiple Sclerosis) and SENTINEL (The Safety and
Efficacy of Natalizumab in Combination with Interferon
Beta-1a in Patients with Relapsing Remitting Multiple
Sclerosis) trials. In addition, there were no early or late
infectious cases of fungal, Pneumocystis jirovecii, JC
virus, Epstein–Barr virus, or cytomegalovirus, and there
was no treatment-related mortality [48]. Altogether,using nonmyeloablative HSCT was crucial in improving
neurological disabilities in RR-MS patients.
A major pathological complication of auto-HSCT may
be the effects reported on brain volume. Saiz et al. [49]
focused on monitoring the evolution of inflammatory
disease activity by suppressing the relapses and Gd+
MRI lesions post-auto-HSCT. Four out of five patients
had a constant or improved EDSS after 3 and 12 months
post-transplantation, but the fifth patient suffered deteri-
oration in their condition during the treatment. For all
of the patients post-auto-HSCT, there was no enhance-
ment of T1 lesions and no enlargement of or new T2 le-
sions (median: 11.8 % appearing). In addition, the corpus
callosum area decreased in all patients at 1-year follow-
up (median declines: 12.4 %) and for two patients there
was no progress at 2 years post-HSCT. These results sug-
gest a positive impact of auto-HSCT on active inflamma-
tion that corresponds with the clinical stabilization of the
five patients at 1 year post-HSCT. Although the five pa-
tients showed improvements in other MRI variables, the
atrophy of the corpus callosum increased. The relation-
ship between the development of brain atrophy and in-
flammatory activity is uncertain. This study indicates the
effectiveness of using auto-HSCT in arresting the inflam-
matory activity; however, the pathological process respon-
sible for brain atrophy was not reversed [49].
Rapid loss of brain volume has been measured a few
months after treatment [50]. Auto-HSCT has seemingly
detrimental effects on the integrity of the brain tissue
that leads to rapid loss of about 1.92 % of brain volume.
A study of SP-MS patients showed that brain atrophy
after auto-HSCT is not constant but declines for the first
2 years after treatment. The reduction in brain volume
may be a result of the significant inflammation seen be-
fore stem cell transplantation is performed. The patho-
logical evidence for this is through the large number of
transected axons seen in MS lesions, marked axonal in-
jury, cortical demyelination, and diffuse inflammation of
the brain observed after histopathological analysis [50].
Histopathological studies have also been carried out on
brain tissue obtained at autopsy from deceased patients
who had been treated with auto-HSCT, and they indicate
ongoing active demyelination. Metz et al. [51] interrogated
brain tissue samples from five patients with chronic le-
sions where they investigated 53 individual white matter
lesions through immunohistochemical and routine stain-
ing techniques. They were able to characterize damaged
axons, activated macrophages/microglial cells, inflamma-
tory infiltrates, and demyelinating activity in these lesions.
Limited numbers of T cells, which were dominated by
CD8+ cytotoxic T cells in the inflammatory infiltrate,
could be observed within the lesions while plasma cells
and B cells were completely absent. Macrophages/
microglial cells were found on the injured tissue and
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active lesion areas. The study concluded that axonal de-
generation and demyelination remain a constant feature
even after auto-HSCT, despite effective immunosup-
pression associated with transplantation [51]. Their
data were supported by other clinical studies, which in-
dicate that there is continued clinical disease progres-
sion in MS patients with high EDSS despite their
special auto-HSCT therapy [52]. The clinical efficacy of
intense immunosuppression with auto-HSCT does not
appear to avoid further progression in MS patients with
high EDSS score (>6.0) [51]. Thus, future HSCT trials
should consider inclusion criteria to be an early stage
of disease course with active relapses of MS, as well as
combinatorial new therapeutic strategies that may pre-
vent ongoing neurodegeneration and demyelination in
progressive MS [51].
A more recent study undertaken by Mancardi et al. [53]
in Italy evaluated the effect of a highly intense condition-
ing regimen followed by auto-HSCT compared with the
immunosuppressive therapy mitoxantrone (MTX, Novan-
trone; EMD Serono, Rockland, MA USA) on the disease
activity of 21 MS patients. This controlled, randomized,
multicenter phase II trial of auto-HSCT led to a signifi-
cant reduction in T2-weighted lesions, Gd+ areas, and an-
nualized relapse rates (ARR) as compared with MTX.
Nine patients (four SP-MS with relapses, three SP-MS,
two RR-MS) were assigned to the auto-HSCT group and
12 patients ended up in the MTX-treatment group (five
RR-MS, three SP-MS, three SP-MS with relapses, one RP-
MS). The first group was given 4 g/m2 cyclophosphamide
and 5 μg/kg body weight filgrastim, along with a high-
dose chemotherapy conditioning regimen, BEAM. Pa-
tients treated with MTX received a 20 mg MTX dose
intravenously and 1 g methylprednisolone diluted in
250 ml 0.9 % saline every month for 6 months. The re-
searchers found that 79 % of patients who experienced
auto-HSCT had fewer new T2 lesions on MRI scans as
compared with the MTX-treated patients by using an
intention-to-treat analysis. However, due to patient drop-
out and technical problems, only 17 of the 21 patients had
MRI scans. Furthermore, there was a complete suppres-
sion of active inflammatory lesions, as demonstrated by
the absence of new Gd+ lesions in the auto-HSCT group
during a 4-year follow-up, although 56 % of MTX-treated
patients had inflammatory activity. Regarding the effect of
ARR over 4 years, ARR reduced in the auto-HSCT pa-
tients (ARR = 0.19) as compared with MTX patients (ARR
= 0.6). Nevertheless, only 48 % of MTX patients demon-
strated progression while 57 % of auto-HSCT patients had
progressed at the end of follow-up. There were no observ-
able differences in EDSS scores between the two groups.
This study demonstrated that for patients with severe pro-
gressive MS, treatment with auto-HSCT is superior totreatment with MTX. The effect is related to the intensity
of the conditioning regimen, which was used to reset the
immune system in MS patients before performing HSCT,
compared with the Nash et al. [54] and Burt et al. [48] tri-
als that were reported earlier in 2015. Although this ran-
domized and controlled study yielded promising results,
the sample size was small. In addition, the clinical results
of the study by Mancardi et al. [53] were lackluster in
comparison with other studies in auto-HSCT, especially
when compared with the reduction in EDSS among MS
patients who enrolled in the Burt et al. [48] study in 2015
as well as the information on quality of life and brain atro-
phy, not investigated in this study.
Criteria to be considered in HSCT in MS patients
There are several criteria that may play a crucial role in
using HSCT as a therapeutic option in the management
of MS, including proposed international multicenter,
randomized clinical trials of HSCT compared with the
best standard of care treatment, MS patient selection in
studies, and long-term follow-up studies of patients from
international registries [29]. Although recent studies
provide a significant improvement in various types of
MS patients’ lives, several vital limitations have been re-
ported [38, 48]. Firstly, the inferences deducted from
HSCT effects cannot be made because most studies
were observational for the treated cohorts without ap-
propriate control groups. Secondly, there has not been
enough information about disease activity before the dis-
ease course and its treatment (and there has been no
long-term follow-up available for certain patients). In
addition, the studies were mostly performed at a single
institution, which may implicate bias.
Conclusion
HSCT is a plausible treatment paradigm for MS patients.
However, auto-HSCT is considered to be a sledgeham-
mer approach for treating MS patients, one that will be
astoundingly effective when used on appropriately se-
lected patients. The reasons for this promising therapy’s
success are its lower toxicity and its ability to replace the
immune system. The future of HSCT trials should dis-
cover novel therapeutic strategies that prevent ongoing
neurodegeneration and demyelination in progressive MS.
The trial designs should consider the reproducibility of
HSCs with sufficient yield and purity, select MS patients
with active inflammatory disease, and use appropriate
conditioning agents.
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